Artelo Biosciences Inc (ARTL) Stock Price, Quote & News

Company Profile

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated/ weight loss with cancer; and ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, depression, post-traumat...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 925 7049

Website: www.artelobio.com

Address:

505 Lomas Santa Fe, Suite 160, Solana Beach, United States

JarvisFlow Aug. 18 at 11:30 AM

D. Boral Capital updates rating for Artelo Biosciences ( $ARTL ) to Buy, target set at 18.

0 · Reply

Gunther77 Aug. 15 at 1:40 PM

$ARTL i don't get it. It looks like they added 600k shares thus nearly doubling, and the share price didn't blink an eye? How is that possible, especially with this stock? What a novice way to increase your market cap.

0 · Reply

Gunther77 Aug. 14 at 5:53 PM

$ARTL i don't know what this crazy idiot has done, and i don't think he does either. I have bought a lot of sketchy stocks through my broker online. Not once, until now, have they refused and said, "you need to call us to buy this". It feels weird not to own $ARTL . I owned this for 4 years and made it through 2 reverse splits, but i think Gorgas may have finally screwed the pooch on this one.

0 · Reply

Fostecare Aug. 14 at 2:29 PM

$ARTL How exactly is ARTL a publicly traded company with volume so lousy? I thought it was measly these past two weeks, but 56 shares traded after one hour of trading today? It comes as no wonder seeing as how this board has only me posting since yesterday. I would not be exaggerating if I suggested ARTL's volume could very well be the worst I've seen of a Nasdaq listed stock. I flipped this several times with each of its rockets these past two months, but now, no longer care to dare.

0 · Reply

d_risk Aug. 13 at 4:04 PM

$ARTL - ARTELO BIOSCIENCES, INC. - 10Q - Updated Risk Factors ARTL’s 10-Q risk factors now spotlight major new risks tied to its Solana (SOL) treasury strategy—including SOL price volatility, regulatory uncertainty, liquidity issues, Nasdaq listing threats, and resource diversion from its core biopharma business—alongside expanded financial, operational, and IP risk disclosures. #Biopharma #IPRisk #MarketVolatility #RegulatoryUncertainty #CryptocurrencyRisk 🟢 Added 🟠 Removed https://d-risk.ai/ARTL/10-Q/2025-08-13

0 · Reply

MrTicker Aug. 13 at 1:29 PM

$ARTL Form D ARTELO BIOSCIENCES, INC. 10K WIZARD 8:28 AM ET 8/13/2025 http://archive.fast-edgar.com/20250813/AIVZC22CZ22IQ2Z2222C22ZVLUAGZZ229T72 Filed on: August 13, 2025

0 · Reply

Flowjob Aug. 12 at 5:13 PM

$ARTL Phase 2 CAReS study in cancer anorexia-cachexia syndrome, expected during the third quarter of 2025. $BDRX Phase 2 eRapa in NMIBC data due mid-2025.

1 · Reply

Just_for_Fun Aug. 12 at 8:53 AM

$ARTL in for A Few Dollars More

0 · Reply

IntoTheStars Aug. 11 at 11:58 PM

$ARTL boune

0 · Reply

LongBallBarn Aug. 11 at 11:24 PM

$ARTL

0 · Reply

Artelo Biosciences Provides Business Update and Reports Second Quarter 2025 Financial Results

Aug 11, 2025, 9:15 AM EDT - 7 days ago

Artelo Biosciences Receives Notice of Allowance from European Patent Office for the Patent Claims for the Intended Commercial Formulation of ART27.13

Aug 4, 2025, 7:30 AM EDT - 14 days ago

Artelo Biosciences Announces $9.475 Million At-the-Market Private Placement to Initiate Solana Treasury Strategy, Becoming First Publicly-Traded Pharmaceutical Company to Adopt SOL as a Core Reserve Asset

Aug 1, 2025, 7:45 AM EDT - 17 days ago

Artelo Biosciences Receives Favorable UK MHRA Guidance for a Phase 1 Trial of ART12.11, the Company's Proprietary CBD:TMP Cocrystal Being Developed for the Treatment of Anxiety and Depression

Jul 9, 2025, 7:50 AM EDT - 5 weeks ago

Artelo Biosciences Announces Positive Preclinical Efficacy Data for ART26.12 in Osteoarthritis Pain at the 35th Annual International Cannabinoid Research Society Symposium

Jul 8, 2025, 3:06 PM EDT - 5 weeks ago

Artelo Biosciences Analyst See It As An Emerging Biotech

Jul 7, 2025, 7:45 AM EDT - 6 weeks ago

Artelo Biosciences Announces Positive Preclinical Efficacy with ART12.11 in Stress-Induced Depression Model

Jun 30, 2025, 7:45 AM EDT - 7 weeks ago

Artelo Biosciences Announces Positive First-in-Human Data for ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain

Jun 26, 2025, 8:00 AM EDT - 7 weeks ago

Artelo Biosciences Announces $1.425 Million At-the-Market Private Placement Financing

Jun 11, 2025, 8:30 AM EDT - 2 months ago

Artelo Biosciences Announces Reverse Stock Split

Jun 5, 2025, 9:00 AM EDT - 2 months ago

Artelo's Fatty Acid Binding Protein 5 Inhibitor, ART26.12, Compares Favorably to Naproxen in an Osteoarthritis Pain Study

Jun 2, 2025, 9:00 AM EDT - 2 months ago

New Independent Review Paper Strengthens Therapeutic Rationale for Artelo's FABP Inhibitor Program in Anxiety and Depression

May 13, 2025, 8:00 AM EDT - 3 months ago

Artelo Biosciences Provides Business Update and Reports First Quarter 2025 Financial Results

Apr 28, 2025, 8:45 AM EDT - 4 months ago

Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating ART26.12's Effectiveness in Treating Psoriasis

Mar 31, 2025, 8:30 AM EDT - 5 months ago

Artelo Biosciences to Present Novel Scientific Insights for ART26.12 at the 4th ACE Drug Discovery Summit on April 3, 2025

Mar 3, 2025, 8:00 AM EST - 6 months ago

Artelo Biosciences Provides Business Update and Reports Fiscal 2024 Year-End Financial Results

Feb 14, 2025, 9:00 AM EST - 6 months ago

Artelo Biosciences Announces New Data on ART12.11 Tablets Showing Improved Pharmacokinetics to Epidiolex®

Feb 11, 2025, 9:00 AM EST - 6 months ago

Artelo Biosciences to Present its New Data on ART12.11 Tablets Compared to Epidiolex at the IMCCB-25 Conference in Bern, Switzerland

Jan 13, 2025, 9:00 AM EST - 7 months ago

Artelo Biosciences Announces Successful Completion of First Cohort in a Phase 1 Study of ART26.12

Dec 9, 2024, 9:15 AM EST - 9 months ago

Artelo Biosciences Announces Presentation of Phase 1 Data with ART27.13 in Cancer-Related Anorexia

Nov 18, 2024, 8:30 AM EST - 9 months ago

Artelo Biosciences to Present Key Data on Three Development Programs at the 7th Cannabinoid Drug Development Summit

Nov 13, 2024, 8:30 AM EST - 9 months ago

Artelo Biosciences Announces Promising New Data on Novel Non-Opioid Treatment Approach for Osteoarthritis Pain at the 13th Annual Musculoskeletal Repair and Regeneration Symposium

Nov 5, 2024, 8:30 AM EST - 10 months ago

Artelo Biosciences Announces Acceptance of ART26.12 into the National Institutes of Health's “Preclinical Screening Platform for Pain” Program

Oct 9, 2024, 9:00 AM EDT - 11 months ago

Artelo Biosciences CEO to Participate in Fireside Chat at the Maxim Group Virtual Healthcare Summit on October 16th

Sep 4, 2024, 9:00 AM EDT - 1 year ago

Artelo Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 13, 2024, 8:00 AM EDT - 1 year ago

Artelo Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 15, 2024, 8:30 AM EDT - 1 year ago

Artelo Biosciences Receives FDA Clearance of its IND Application for ART26.12, a Selective Fatty Acid Binding Protein 5 Inhibitor

Jul 3, 2024, 9:00 AM EDT - 1 year ago

Artelo Biosciences Presents Comparative Data from Key Preclinical Studies on ART12.11 at the 34th Annual International Cannabinoid Research Society Symposium

Jun 4, 2024, 8:30 AM EDT - 1 year ago

Artelo Biosciences Presents Important New Data on ART26.12 at the 57th Annual Scientific Meeting of the British Pain Society

May 29, 2024, 8:30 AM EDT - 1 year ago

Artelo Biosciences Presents Highly Encouraging Data Towards Developing a Solid Dosage Form of ART12.11 at CT-CANN24

May 13, 2024, 8:00 AM EDT - 1 year ago

Artelo Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update

May 10, 2024, 9:00 AM EDT - 1 year ago

Artelo Biosciences to Present at the Pharma Partnering Summit 2024 on May 14th

Apr 23, 2024, 8:30 AM EDT - 1 year ago

Artelo Biosciences Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer Therapy

Apr 22, 2024, 8:30 AM EDT - 1 year ago

Artelo Biosciences CEO to Appear on Benzinga All Access on April 23rd at Approximately 10:50 AM Eastern Time

Mar 25, 2024, 8:00 AM EDT - 1 year ago

Artelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business Update

Mar 12, 2024, 9:15 AM EDT - 1 year ago

Artelo Biosciences Selected as a Finalist in Johnson & Johnson's Innovation Challenge

Feb 15, 2024, 9:00 AM EST - 1 year ago

Artelo Biosciences to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20th

Jan 23, 2024, 8:30 AM EST - 1 year ago

Artelo Biosciences Announces Publication of New Peer-Reviewed Pre-Clinical Research Demonstrating ART26.12's Effectiveness in Treating and Preventing Oxaliplatin-Induced Peripheral Neuropathy

Jan 8, 2024, 8:30 AM EST - 1 year ago

Artelo Biosciences Announces Selection of Worldwide Clinical Trials as Clinical Research Organization to Support First-in-Human Study of ART26.12

Dec 5, 2023, 8:30 AM EST - 1 year ago

Artelo Biosciences Presents New Preclinical Data on ART12.11 at the 4th Annual Med-Cannabis 2023 Conference in Germany

Nov 30, 2023, 9:00 AM EST - 1 year ago

Artelo Biosciences to Present Important New Preclinical Data on ART12.11 at the 4th Annual Med-Cannabis 2023 Conference in Germany

Nov 13, 2023, 8:00 AM EST - 1 year ago

Artelo Biosciences Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 9, 2023, 9:00 AM EST - 1 year ago

Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating Protective Properties of ART27.13 Against Muscle Degeneration Caused by Certain Cancers

Nov 2, 2023, 8:30 AM EDT - 1 year ago

Artelo Biosciences to Present Preclinical Data Showcasing Research on ART26.12 and ART12.11 in Anxiety and Depression at Neuroscience 2023

Oct 4, 2023, 8:30 AM EDT - 2 years ago

Principal Investigator of Artelo's CAReS Trial to Participate in Medical Expert Webinar Hosted by H.C. Wainwright to Discuss Current Development Strategies for Cancer-Related Anorexia and Cachexia

Sep 13, 2023, 8:30 AM EDT - 2 years ago

Artelo Biosciences to Present at the 13th Congress of the European Pain Federation on September 20th

Sep 7, 2023, 8:00 AM EDT - 2 years ago

Artelo Biosciences Completes Positive Pre-IND Meeting with FDA for ART26.12

Sep 6, 2023, 9:00 AM EDT - 2 years ago

Artelo Biosciences to Present at the 6th Cannabinoid-Derived Drug Development Summit on September 12th

Sep 5, 2023, 9:00 AM EDT - 2 years ago

Artelo Biosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference on September 13th

Aug 10, 2023, 8:00 AM EDT - 2 years ago

Artelo Biosciences Reports Second Quarter 2023 Financial Results and Provides Business Update

JarvisFlow Aug. 18 at 11:30 AM

D. Boral Capital updates rating for Artelo Biosciences ( $ARTL ) to Buy, target set at 18.

0 · Reply

Gunther77 Aug. 15 at 1:40 PM

0 · Reply

Gunther77 Aug. 14 at 5:53 PM

0 · Reply

Fostecare Aug. 14 at 2:29 PM

0 · Reply

d_risk Aug. 13 at 4:04 PM

0 · Reply

MrTicker Aug. 13 at 1:29 PM

$ARTL Form D ARTELO BIOSCIENCES, INC. 10K WIZARD 8:28 AM ET 8/13/2025 http://archive.fast-edgar.com/20250813/AIVZC22CZ22IQ2Z2222C22ZVLUAGZZ229T72 Filed on: August 13, 2025

0 · Reply

Flowjob Aug. 12 at 5:13 PM

$ARTL Phase 2 CAReS study in cancer anorexia-cachexia syndrome, expected during the third quarter of 2025. $BDRX Phase 2 eRapa in NMIBC data due mid-2025.

1 · Reply

Just_for_Fun Aug. 12 at 8:53 AM

$ARTL in for A Few Dollars More

0 · Reply

IntoTheStars Aug. 11 at 11:58 PM

$ARTL boune

0 · Reply

LongBallBarn Aug. 11 at 11:24 PM

$ARTL

0 · Reply

Bigsaltyone Aug. 11 at 7:09 PM

$ARTL

0 · Reply

PharmaExpert Aug. 11 at 4:48 PM

$AKBA, $ARTL, $VSTM, $CLOV, $NLTX 🔥🔥🔥🔥🔥

0 · Reply

prismmarketview Aug. 11 at 4:21 PM

(NASDAQ: $ARTL) @ArteloBio earns a major milestone with the European Patent Office granting allowance for ART27.13's commercial injectable formulation, offering protection through December 2041. This advancement strengthens their pipeline in cancer-related anorexia treatment. https://prismmarketview.com/artelo-biosciences-secures-european-patent-approval-for-art27-13-formulation/

0 · Reply

Bigsaltyone Aug. 11 at 2:41 PM

$ARTL this one moves quick!!

0 · Reply

DARKP00L Aug. 11 at 1:17 PM

$ARTL 09:17 on Aug. 11 2025 Artelo Biosciences Secures European Patent For ART27.13 Commercial Formulation, Extending Protection Through 2041; Phase 2 Trial Advances For Cancer-Related Anorexia Treatment #tradeideas

0 · Reply

MrTicker Aug. 11 at 1:17 PM

$ARTL Artelo Biosciences Secures European Patent For ART27.13 Commercial Formulation, Extending Protection Through 2041; Phase 2 Trial Advances For Cancer-Related Anorexia Treatment BENZINGA 8:17 AM ET 8/11/2025

0 · Reply

MrTicker Aug. 11 at 1:16 PM

$ARTL Artelo Biosciences Receives Notice of Allowance from European Patent Office for the Patent Claims for the Intended Commercial Formulation of ART27.13 GLOBENEWSWIRE 8:15 AM ET 8/11/2025

0 · Reply

Deuce15 Aug. 9 at 4:04 PM

$ARTL I hope everyone involved in the pump and dump for this stock goes to jail.

0 · Reply

GreenMadness00 Aug. 7 at 4:28 PM

$ARTL back to $1

0 · Reply

verusabiz Aug. 6 at 4:05 PM

$ARTL Another day and no volume absolutely means nothing to the stock price

0 · Reply

JarvisFlow Aug. 6 at 1:09 PM

D. Boral Capital has updated their rating for Artelo Biosciences ( $ARTL ) to Buy with a price target of 18.

0 · Reply

LongBallBarn Aug. 6 at 9:48 AM

$ARTL $IMNN $DOMH $ORIS

0 · Reply

Market Cap	7.06M
Revenue (ttm)	0.00
Net Income (ttm)	-9.83M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	7,657
Avg Vol	830,423
Day's Range	N/A - N/A
Shares Out	704,000.00
Stochastic %K	83%
Beta	1.36
Analysts	Strong Sell
Price Target	$18.00